How to Value a Market Research Firm in 2026

Market research is one of those industries where two firms with identical revenue can sell for wildly different prices. A $5M custom research shop that lives project-to-project might sell for 3.5x EBITDA. A $5M syndicated research firm with a subscription revenue base can sell for 7x or more. Same headcount, same office, completely different buyer math.

The spread comes down to one question buyers ask constantly: how much of next year's revenue is already booked? Everything else — methodology, panel assets, industry specialization — funnels into that single answer.

The Baseline Multiple Range

Market research firms generally sell for 4.0-7.0x EBITDA, with the median around 5.0-5.5x. Pure custom shops with project-based revenue trade at the lower end (3.5-5x). Firms with syndicated products, subscription tracking studies, or proprietary panel assets trade at the higher end (6-8x), and a handful of strategic assets have cleared 9-10x when sold to acquirers like Kantar, Ipsos, NielsenIQ, or dentsu.

Sub-$3M revenue firms sometimes get valued on SDE instead of EBITDA, typically in the 2.5-4x SDE range, because the buyer pool at that size is individual operators and small competitors rather than strategics. Above $5M EBITDA, the institutional buyers show up and multiples expand.

Custom Research vs Syndicated: The Critical Distinction

If you only remember one thing about valuing a research firm, remember this: buyers pay 2x more per dollar of EBITDA for syndicated revenue than for custom project revenue. The reason is straightforward — syndicated revenue renews.

Custom research is bespoke. A client hires you to answer a specific question: will this new product concept work, why are we losing market share to a competitor, what does our ideal customer look like. You scope the project, you run the fieldwork, you deliver findings, and the engagement ends. The client might come back next year, or they might not. Custom shops routinely discover that 30-40% of prior-year revenue doesn't repeat, which is why buyers discount them.

Syndicated research is a product. You build a tracking study, a category report, a brand health monitor, or a subscription dashboard, and you sell access to multiple clients who renew annually. The cost to produce the next wave is largely fixed, but each new subscriber is nearly pure margin. A firm with $2M in syndicated subscriptions renewing at 85% is worth dramatically more per dollar than a firm with $2M in custom project backlog.

The hybrid model — custom research anchored by 1-2 syndicated products — is where I see the best outcomes. One firm I tracked added a quarterly category tracker to their custom business, grew it to $1.2M in recurring subscriptions over three years, and saw their valuation multiple expand from 4.3x to 6.1x EBITDA at exit.

Panel Assets and Proprietary Data

Owning a panel — a database of pre-recruited respondents you can survey on demand — is one of the most valuable assets a research firm can have, and it's one of the most consistently undervalued by sellers.

Buyers like Dynata, Cint, and Prodege have spent hundreds of millions acquiring panel assets because panels are expensive to build, defensible once established, and directly monetizable. A B2B panel of 50,000 IT decision-makers is worth more than a consumer panel of 500,000 general population respondents, because B2B recruitment is so much harder.

If you own a panel, document it carefully before going to market: panel size, active response rates, profile depth (what attributes you can target on), average engagement frequency, and replacement rate. Buyers will want to model the panel as a standalone asset, and firms that can articulate panel economics separately from the research services business get credit for both.

Firms without panels aren't doomed — most use online sample providers like Cint or Prodege and pay per complete. But the margin profile is permanently lower, and so is the multiple. One workaround: if you've built a deep list of recurring qualitative respondents (executives, physicians, category experts), that functions as a de facto panel and deserves the same treatment in your CIM.

Client Retention and Concentration

Research firms live and die on client retention. Buyers will ask for a cohort analysis: of clients who engaged you in year one, how many are still engaging in year two, three, four, five? Firms with 80%+ annual retention get premium valuations. Firms with 50% retention get discounted aggressively because the buyer has to assume they're constantly replacing lost revenue.

Concentration is the other side of the coin. The typical research firm has ugly concentration — often 40-60% of revenue from the top 3 clients, because large consumer brands, pharma companies, and financial services firms tend to consolidate research spend with a small roster of preferred vendors. Buyers know this and will haircut your multiple accordingly.

The best defense is contract length. If your top client has a three-year master services agreement with committed annual spend, that's very different from a top client who issues quarterly purchase orders. Long-dated MSAs with named scopes and committed minimums deserve to be called out prominently in your deal materials.

Vertical Specialization Matters

Generalist research firms get average multiples. Firms that have built deep specialization in pharma, healthcare, financial services, tech, or CPG consistently get 0.5-1.5x better multiples, because strategic buyers pay premiums for industry access.

Pharma market research is the standout example. Firms specializing in HCP research, patient journey studies, and payer insights regularly sell at 7-9x EBITDA to acquirers like M3 (through M3 Global Research), WPP's CMI Media, or Clarivate. A comparable generalist firm would sell at 5x. The pharma premium exists because regulatory knowledge, HCP panel access, and methodology experience are genuinely hard to replicate.

Healthcare-adjacent, financial services, and B2B tech also attract specialist premiums. Consumer goods research is more competitive — the category is saturated, and margins have compressed as CPG clients push work to lower-cost providers and DIY platforms.

What Buyers Dig Into During Diligence

Research firm diligence has some industry-specific traps.

Revenue recognition. Custom projects billed upfront but delivered over 6-9 months create a mismatch between cash and accrual revenue that confuses buyers. Make sure your accounting treats project revenue on a percentage-of-completion basis, not cash-received. Deals have died over revenue recognition disputes.

Pipeline quality. Buyers will ask for your 12-month pipeline broken into proposal-out, verbal-commit, and signed-contract buckets. If 80% of your projected revenue is in proposal-out, you're going to get pushed on close rates. Firms that can show 6 months of signed backlog going into a deal close on better terms.

Key person dependency. If you're the methodologist and every major project ends up on your desk, buyers will treat the firm as a consultancy built around one person. Building out senior research directors who can front client relationships independently is the single biggest lever to expand your multiple.

Technology stack. Buyers increasingly ask about your tech stack — survey platforms (Qualtrics, Forsta, Alchemer), analytics tools, AI-assisted coding, dashboard delivery. Firms still delivering PowerPoint decks via email look dated, and buyers will assume you need investment to modernize.

How to Maximize Your Exit

If you're 2-3 years from selling, the highest-ROI moves:

Build at least one syndicated product. Even a modest quarterly tracker at $150K-$300K in recurring subscriptions will shift how buyers see you.

Lock in your top clients with MSAs. Committed multi-year agreements with named scopes are worth real multiple expansion.

Document your panel or respondent database. Whatever you have, surface it as a quantifiable asset with engagement metrics.

Build a second-in-command. A research director who owns client relationships independently is the difference between a 4x and a 6x outcome.

Lean into vertical depth. If you're generalist, pick the vertical where you have the most traction and double down. Firms known for one thing sell better than firms known for everything.

The Bottom Line

Market research firms are valued on how predictable their next year looks. Custom project shops with high churn and owner-centric client relationships sell at the bottom of the range. Specialized firms with syndicated products, deep panels, long-dated MSAs, and delegated client ownership sell at the top. The gap between those two outcomes on a $5M revenue firm can easily be $4-8 million in total consideration. That's worth 18-24 months of focused preparation.